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The antimicrobial susceptibility of five Lyme disease spirochete strains (two human and
three tick isolates) was determined. A macrodilution broth technique was used to determine on
three separate testoccasions theminimal inhibitoryconcentrations (MICs) ofseven antibiotics.
The Lyme disease spirochete was most susceptible to erythromycin with a MIC of c 0.06
sg/ml. The spirochete was also found to be susceptible to minocycline, ampicillin, dox-
ycycline, andtetracycline-HCL with respective mean MICs of < 0.13, c 0.25, c 0.63, and c
0.79 gg/ml. Thespirochete was moderatelysusceptible to penicillin G with a mean MIC of0.93
lAg/ml. All strains were resistant to rifampin at the highest concentration tested (16.014g/ml).
Lyme disease is a recently described human disorder characterized initially by
erythema chronicum migrans (ECM) that is often followed by cardiac, neurologic,
and/or arthritic complications. ECM was initially described in Europe where treat-
ment with penicillin was effective [1-3]. Subsequently, it has been reported in the
United States that ECM andits associated sequelae maybeprevented orameliorated
by treatment with antimicrobials such as penicillin and tetracycline [4,5]. In 1983,
Steere et al. [6] found that tetracycline was superior to penicillin in preventing these
sequelae. Until recently, in vitro evaluation of these clinical observations was not
possible because the etiologic agent for this disease had not been recovered.
A spirochete referred to here as the Lyme disease spirochete (LDS) has now been
isolated [7-12]. To compare the reported clinical efficacy of antimicrobials with in
vitro results and to select additional antimicrobials of potential therapeutic benefit,
we tested the efficacy of seven antimicrobials in an in vitro assay against five LDS
strains (Table 1). To ensure the detection of any possible difference in strain-to-
strain antimicrobial susceptibility, we selected strains to represent different
geographical locations and various hosts because of: (a) the occurrence of Lyme
disease or ECM in various areas in theUnited States and other countries [13-18]; (b)
the isolation of LDS from Ixodes dammini ticks in the United States [10-12] and I.
ricinis ticks from Switzerland [7]; and (c) the isolation of LDS from blood,
cerebrospinal fluid, and ECM lesions of Lyme disease patients [8,12]. We report
here a brief review of these findings, which are reported in greater detail elsewhere
[19].
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Suppliers and Sources of the Lyme Disease Spirochete Strains Tested
Strain
Identification Supplier Source
FIS 001 A.G. Barbour
(B31)b Ixodes dammini tick from
Shelter Island, NY
FIS 004 A.C. Steerec (243) Ixodes dammini tick from
Great Island, MA
FIS 005 A.C. Steere (245) Human blood from a Lyme
disease patient in CT
FIS 008 A.G. Barbour Ixodes ricinus tick from
Switzerland
FIS 033 J.L. Benachd Human blood from a Lyme
disease patient in NY
aRocky Mountain Laboratories, National Institute of Health, Hamilton, Montana
bSupplier's strain identification is given in parentheses.
cYale University School of Medicine, New Haven, Connecticut
dNew York State Department of Health and State University of New York at Stony Brook, Stony
Brook, New York
MATERIALS AND METHODS
For our study, Barbour, Stoenner, Kelly (BSK) medium [7; Barbour AG: Per-
sonal communication] was used and prepared as previously described [11]. Since we
had not used BSK medium previously for in vitro antimicrobial susceptibility
testing, we first determined its effects on antimicrobial activity by testing
simultaneously two control organisms, Staphylococcus aureus ATCC 29213 and
Streptococcus faecalis ATCC 29212, in BSK and cation supplemented Mueller-
Hinton broth media containing each antimicrobial to be used in our study (Table 2).
A macrodilution broth technique was used for both control organisms and LDS to
determine the minimal inhibitory concentrations (MICs) of seven antimicrobials on
three separate occasions. The antimicrobials tested and their respective twofold dilu-
TABLE 2
Antimicrobials, Susceptibility Criteria, and Concentrations to
Which the Lyme Disease Spirochete Was Tested
Susceptibility Criteria b
Moderately Concentrationsb'
Antimicrobic Susceptible Susceptible Resistant Tested
Ampicillin c 1.0 2.0-16.0 > 16.0 0.25-16.0
Penicillin G <0.12 0.25-16.0 > 16.0 0.06-4.0
Erythromycin c0.5 1.0-4.0 > 4.0 0.06-4.0
Doxycycline c 1.0 2.0-8.0 > 8.0 0.25-16.0
Minocycline c 1.0 2.0-8.0 > 8.0 0.12-8.0
Tetracycline-HCl c 1.0 2.0-8.0 > 8.0 0.25-16.0
Rifampin <2.0 4.0 > 4.0 0.25-16.0
aAs suggested by the National Committee for Clinical Laboratory Standards [20]
bIn ug/ml
cIn serial twofold dilutions
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tion ranges are listed in Table 2. Stock solutions (1,056 itg/ml) of each an-
timicrobial, except rifampin, were prepared, filter-sterilized (pore size of0.2A), and
stored at -70°C in 5 ml aliquots until ready to use. Rifampin at 528 tg/ml was
made fresh before each test and was not filtered. A series of twofold working dilu-
tions was prepared on test day for each of the seven antimicrobials. The dilutions
were prepared by the method recommended by the National Committee for Clinical
Laboratory Standards (NCCLS) [20]. One-tenth ml ofthe appropriate working dilu-
tion was added to culture tubes (13 x 100, plastic, No. 2027, Falcon, Oxnard,
California) containing 6.4 ml ofBSK medium. Thesetubes andgrowth controltubes
(BSK without antimicrobials) were inoculated to a final density of 105 cells per ml
with a five-day-old culture ofthe appropriate LDS strain in BSK medium containing
10' actively growing cells per ml.
In testing the effect ofBSK medium on antimicrobial activity and for quality con-
trol of the antimicrobials during each of the three test runs, S. aureus and S.
faecalis, grown on heart infusion agar supplemented with 5 percent defibrinated
rabbit blood for 18-20 hours at 33°C in air, were suspended in Mueller-Hinton
broth (107 cells per ml) and similarly inoculated into separate sets of tubes contain-
ing the appropriately diluted antimicrobals. After 120 hours' incubation in air at
33°C the numbers of motile LDS in test cultures were determined by darkfield
microscopy and a Petroff-Hausser bacteria counter. Three counts were taken and
averaged for each culture. The least concentration of antimicrobial that had < 101
motile LDS per ml with no noticeable cell sediment was considered the MIC. After
20 hours' incubation in air at 33°C, MICs were determined for S. aureus and S.
faecalis. The least concentration of antimicrobial that completely inhibited growth
(no turbidity and cell sediment) as determined by the unaided eye was considered the
MIC.
RESULTS
In the MIC comparison study our results on media influence showed that MICs
for the evaluated antimicrobials were similar and that they were within acceptable
tolerances (- 1 doubling dilution) of the expected values. Guided by these results
and the susceptibility standards recommended by the NCCLS [20] for the an-
timicrobials tested (Table 2), we found that all the strains of LDS tested were either
susceptible or moderately susceptible to all of the antimicrobials evaluated except
rifampin (Table 3). Of the beta-lactams tested, ampicillin was more active than
TABLE 3
MICs of Seven Antimicrobials and Their Susceptibility Interpretation for Five Strains of Lyme Disease
Spirochete
MICs (ug/ml)
Susceptibility
Antimicrobic Class Meana Range Interpretation
Ampicillin Beta-lactam c0.25 0 Susceptible
Penicillin G Beta-lactam 0.93 0.25-2.0 Moderately susceptible
Erythromycin Macrolide c0.06 0 Susceptible
Doxycycline Tetracycline <0.63 <0.25-2.0 Susceptible
Minocycline Tetracycline s 0.13 <0.12-0.25 Susceptible
Tetracycline-HCl Tetracycline <0.79 <0.25-2.0 Susceptible
Rifampin Rifamycin > 16.0 0 Resistant
,Geometric mean of 15 determinations; three determinations were made for each of the five strains of
Lyme disease spirochete tested.
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penicillin G; of the tetracyclines, minocycline was more active than either
tetracycline-HCl or doxycycline; and the macrolide erythromycin had the lowest
MIC of all the antimicrobials tested.
DISCUSSION
The fact that penicillin G and tetracycline-HCl were active against LDS in vitro
supports the observations ofSteere et al. [5,6] that thetherapeutic use ofthese drugs
reduces the duration ofECM and either prevents or ameliorates neurologic, cardiac,
or arthritic sequelae. Our data also show that other antimicrobials were more effec-
tive than these drugs in inhibiting the growth of LDS, suggesting that differences in
efficacy in vivo might be expected from different penicillin or tetracycline prepara-
tions.
The reasons for the contrasting results between the high in vitro activity of
erythromycin and the poorer efficacy in vivo when compared to penicillin and
tetracycline are unclear. Such discrepancies between high in vitro activity and lesser
clinical efficacy may be seen with other organisms (e.g., Legionella) [21]. The
phenomenon emphasizes that our results provide a guide only to antimicrobials that
may be effective in vivo.
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